Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma.
Vaughn
Michael P
MP
D000085:Acetates / Q000627:therapeutic use*; D000485:Allergens / Q000008:administration & dosage; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy; D003521:Cyclopropanes; D003888:Desensitization, Immunologic; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D007279:Injections, Subcutaneous; D010349:Patient Compliance; D011804:Quinolines / Q000627:therapeutic use*; D013440:Sulfides
D000085:Acetates; D000485:Allergens; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; C093875:montelukast